Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 20 | 2023 | 492 | 1.770 |
Why?
|
| Health Care Costs | 10 | 2019 | 360 | 1.190 |
Why?
|
| Quality-Adjusted Life Years | 16 | 2021 | 104 | 1.010 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2021 | 32 | 0.890 |
Why?
|
| Rhytidoplasty | 1 | 2022 | 10 | 0.810 |
Why?
|
| Decision Support Techniques | 5 | 2019 | 279 | 0.790 |
Why?
|
| Drugs, Generic | 1 | 2021 | 13 | 0.790 |
Why?
|
| Drug Costs | 1 | 2021 | 61 | 0.760 |
Why?
|
| Wound Healing | 4 | 2019 | 454 | 0.700 |
Why?
|
| Scleroderma, Localized | 1 | 2018 | 3 | 0.640 |
Why?
|
| Raynaud Disease | 1 | 2018 | 4 | 0.640 |
Why?
|
| Skin Ulcer | 1 | 2018 | 32 | 0.620 |
Why?
|
| Wound Closure Techniques | 1 | 2017 | 23 | 0.570 |
Why?
|
| Primary Prevention | 1 | 2017 | 163 | 0.520 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 339 | 0.510 |
Why?
|
| Insurance Coverage | 4 | 2023 | 121 | 0.490 |
Why?
|
| Prescription Drugs | 1 | 2015 | 52 | 0.490 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 257 | 0.480 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 604 | 0.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1250 | 0.430 |
Why?
|
| Forehead | 2 | 2022 | 13 | 0.420 |
Why?
|
| Models, Economic | 5 | 2019 | 51 | 0.370 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 1614 | 0.330 |
Why?
|
| Fingers | 2 | 2019 | 63 | 0.320 |
Why?
|
| Replantation | 2 | 2019 | 54 | 0.310 |
Why?
|
| Prognosis | 4 | 2019 | 4488 | 0.260 |
Why?
|
| United States | 15 | 2023 | 10487 | 0.260 |
Why?
|
| Education, Medical, Continuing | 2 | 2017 | 139 | 0.260 |
Why?
|
| Humans | 35 | 2023 | 122292 | 0.250 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 605 | 0.240 |
Why?
|
| Insurance, Health | 2 | 2023 | 134 | 0.240 |
Why?
|
| Medicare | 4 | 2016 | 418 | 0.230 |
Why?
|
| Research Design | 2 | 2018 | 646 | 0.230 |
Why?
|
| Sex Reassignment Surgery | 1 | 2023 | 10 | 0.220 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 171 | 0.220 |
Why?
|
| Tissue Expansion | 1 | 2022 | 14 | 0.210 |
Why?
|
| Rhinoplasty | 1 | 2023 | 44 | 0.210 |
Why?
|
| Eyebrows | 1 | 2022 | 13 | 0.210 |
Why?
|
| Rejuvenation | 1 | 2022 | 10 | 0.200 |
Why?
|
| Amputation, Traumatic | 2 | 2019 | 10 | 0.200 |
Why?
|
| Skin | 2 | 2022 | 503 | 0.200 |
Why?
|
| Finger Injuries | 2 | 2019 | 17 | 0.200 |
Why?
|
| Cicatrix | 1 | 2022 | 125 | 0.190 |
Why?
|
| Ear, External | 1 | 2021 | 22 | 0.190 |
Why?
|
| Arteries | 2 | 2019 | 219 | 0.180 |
Why?
|
| Vascular Grafting | 2 | 2019 | 44 | 0.180 |
Why?
|
| Risk Assessment | 4 | 2019 | 3307 | 0.180 |
Why?
|
| Surgical Flaps | 1 | 2022 | 205 | 0.180 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2020 | 10 | 0.180 |
Why?
|
| Orphan Drug Production | 1 | 2020 | 5 | 0.180 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 9 | 0.180 |
Why?
|
| Endoscopy | 1 | 2022 | 282 | 0.170 |
Why?
|
| Graft Survival | 2 | 2019 | 522 | 0.170 |
Why?
|
| Surgery, Plastic | 1 | 2021 | 110 | 0.170 |
Why?
|
| Leeching | 1 | 2019 | 1 | 0.160 |
Why?
|
| Clinical Competence | 2 | 2016 | 972 | 0.160 |
Why?
|
| Perforator Flap | 1 | 2019 | 9 | 0.160 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 78 | 0.160 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2020 | 241 | 0.160 |
Why?
|
| Dermatologic Agents | 1 | 2018 | 30 | 0.160 |
Why?
|
| Gross Domestic Product | 1 | 2018 | 1 | 0.150 |
Why?
|
| Life Tables | 1 | 2018 | 28 | 0.150 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2018 | 45 | 0.150 |
Why?
|
| Triterpenes | 1 | 2018 | 21 | 0.150 |
Why?
|
| Treatment Outcome | 11 | 2021 | 12043 | 0.150 |
Why?
|
| Upper Extremity | 1 | 2018 | 53 | 0.150 |
Why?
|
| Male | 14 | 2023 | 59517 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1247 | 0.140 |
Why?
|
| Decision Making | 3 | 2017 | 650 | 0.140 |
Why?
|
| Income | 1 | 2018 | 133 | 0.140 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2018 | 105 | 0.140 |
Why?
|
| Nutrition Therapy | 1 | 2017 | 12 | 0.140 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2018 | 139 | 0.140 |
Why?
|
| Educational Measurement | 2 | 2016 | 321 | 0.140 |
Why?
|
| Survival Rate | 2 | 2019 | 1997 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2015 | 1192 | 0.140 |
Why?
|
| Societies, Medical | 2 | 2021 | 673 | 0.130 |
Why?
|
| Certification | 1 | 2016 | 69 | 0.130 |
Why?
|
| Developing Countries | 1 | 2018 | 270 | 0.130 |
Why?
|
| Female | 13 | 2021 | 64882 | 0.130 |
Why?
|
| Choice Behavior | 2 | 2014 | 131 | 0.130 |
Why?
|
| Regeneration | 1 | 2018 | 202 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 99 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 352 | 0.130 |
Why?
|
| Health Policy | 2 | 2014 | 208 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2020 | 767 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 428 | 0.120 |
Why?
|
| Nerve Block | 1 | 2015 | 68 | 0.120 |
Why?
|
| Malnutrition | 1 | 2017 | 196 | 0.110 |
Why?
|
| Ischemia | 2 | 2019 | 342 | 0.110 |
Why?
|
| Anesthesiology | 1 | 2015 | 97 | 0.110 |
Why?
|
| Ultrasonography, Interventional | 1 | 2015 | 196 | 0.110 |
Why?
|
| Global Health | 1 | 2018 | 555 | 0.110 |
Why?
|
| Efficiency | 1 | 2013 | 57 | 0.110 |
Why?
|
| Sympathectomy | 1 | 2012 | 7 | 0.110 |
Why?
|
| Health Care Rationing | 1 | 2013 | 58 | 0.100 |
Why?
|
| Patients | 1 | 2013 | 120 | 0.100 |
Why?
|
| Health Expenditures | 1 | 2013 | 102 | 0.100 |
Why?
|
| Perception | 1 | 2013 | 215 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 271 | 0.100 |
Why?
|
| Lower Extremity | 1 | 2012 | 178 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 507 | 0.090 |
Why?
|
| SEER Program | 3 | 2016 | 193 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 2817 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5013 | 0.090 |
Why?
|
| Aged | 9 | 2020 | 18783 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 581 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 845 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 1680 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1407 | 0.080 |
Why?
|
| Hospitalization | 1 | 2017 | 1727 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 1008 | 0.080 |
Why?
|
| Middle Aged | 5 | 2019 | 25636 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 3626 | 0.080 |
Why?
|
| Child | 3 | 2022 | 24063 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2014 | 841 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 815 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2019 | 15853 | 0.070 |
Why?
|
| Logistic Models | 3 | 2019 | 1772 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2012 | 561 | 0.070 |
Why?
|
| Heart Failure | 1 | 2020 | 2125 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 861 | 0.070 |
Why?
|
| Registries | 3 | 2018 | 1367 | 0.070 |
Why?
|
| Kidney | 1 | 2012 | 1340 | 0.060 |
Why?
|
| Quality of Life | 1 | 2015 | 1913 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 6289 | 0.060 |
Why?
|
| Hypertension | 1 | 2012 | 1274 | 0.060 |
Why?
|
| Quality Improvement | 2 | 2021 | 620 | 0.060 |
Why?
|
| Gender Identity | 1 | 2023 | 68 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2017 | 606 | 0.050 |
Why?
|
| Nose | 1 | 2023 | 92 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 6181 | 0.050 |
Why?
|
| Face | 1 | 2023 | 178 | 0.050 |
Why?
|
| Markov Chains | 2 | 2012 | 79 | 0.050 |
Why?
|
| Esthetics | 1 | 2021 | 37 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2021 | 118 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1298 | 0.050 |
Why?
|
| Epoetin Alfa | 1 | 2020 | 12 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 270 | 0.040 |
Why?
|
| Publishing | 1 | 2021 | 104 | 0.040 |
Why?
|
| Comorbidity | 2 | 2015 | 1490 | 0.040 |
Why?
|
| Suture Techniques | 1 | 2021 | 199 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2021 | 384 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 186 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2014 | 4643 | 0.040 |
Why?
|
| Neck Dissection | 1 | 2019 | 18 | 0.040 |
Why?
|
| Crush Injuries | 1 | 2019 | 5 | 0.040 |
Why?
|
| Degloving Injuries | 1 | 2019 | 3 | 0.040 |
Why?
|
| Hyperemia | 1 | 2019 | 25 | 0.040 |
Why?
|
| Neoplasms | 1 | 2013 | 2753 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 105 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 2777 | 0.040 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 65 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2018 | 25 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2018 | 24 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 336 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2018 | 143 | 0.040 |
Why?
|
| Streptokinase | 1 | 2017 | 20 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2797 | 0.040 |
Why?
|
| American Medical Association | 1 | 2016 | 7 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2018 | 185 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2018 | 445 | 0.030 |
Why?
|
| Specialty Boards | 1 | 2016 | 21 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2019 | 303 | 0.030 |
Why?
|
| Adult | 4 | 2019 | 28730 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 112 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2016 | 49 | 0.030 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 16 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2017 | 176 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 349 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 239 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 199 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2019 | 576 | 0.030 |
Why?
|
| Decision Making, Organizational | 1 | 2015 | 4 | 0.030 |
Why?
|
| Economics, Medical | 1 | 2015 | 7 | 0.030 |
Why?
|
| Comprehension | 1 | 2015 | 73 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 300 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 468 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2021 | 13777 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 267 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 203 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1022 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 97 | 0.030 |
Why?
|
| Video Recording | 1 | 2015 | 181 | 0.030 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2014 | 94 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 1272 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2014 | 197 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2018 | 798 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 1034 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 2440 | 0.030 |
Why?
|
| Learning | 1 | 2015 | 358 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1234 | 0.020 |
Why?
|
| Psychometrics | 1 | 2015 | 666 | 0.020 |
Why?
|
| Catheterization | 1 | 2012 | 238 | 0.020 |
Why?
|
| Patient Participation | 1 | 2013 | 216 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 744 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 1158 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 857 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2012 | 433 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 423 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 994 | 0.020 |
Why?
|
| Communication | 1 | 2013 | 505 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1244 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1575 | 0.020 |
Why?
|
| Animals | 2 | 2019 | 33723 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 8759 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2015 | 1153 | 0.020 |
Why?
|
| Endovascular Procedures | 1 | 2012 | 710 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 12302 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 17548 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 18939 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 1822 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 9901 | 0.010 |
Why?
|